{"id":5115,"date":"2025-11-04T21:28:58","date_gmt":"2025-11-04T18:28:58","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5115"},"modified":"2025-11-05T00:18:00","modified_gmt":"2025-11-04T21:18:00","slug":"sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down\/","title":{"rendered":"Terapias de DMD com salto de exon da Sarepta falham em estudo confirmat\u00f3rio, pre\u00e7o das a\u00e7\u00f5es cai"},"content":{"rendered":"<p class=\"wp-block-paragraph\">As dificuldades com o gene Sarepta Therapeutics s\u00f3 pioram. Em pacientes com distrofia muscular de Duchenne, a empresa descobriu que seus tratamentos de exclus\u00e3o de \u00e9xons, Vyondys 53 e Amondys 45, n\u00e3o melhoraram significativamente a fun\u00e7\u00e3o motora. <a href=\"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2025-financial\" target=\"_blank\" rel=\"noreferrer noopener\">An\u00fancio da Sarepta<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Na negocia\u00e7\u00e3o pr\u00e9-mercado de ter\u00e7a-feira, as a\u00e7\u00f5es da empresa de biotecnologia estavam sendo negociadas a $15,60, uma queda de 36% em rela\u00e7\u00e3o ao pre\u00e7o de fechamento das a\u00e7\u00f5es de segunda-feira, de $24,45.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Em uma carta enviada a clientes na manh\u00e3 de ter\u00e7a-feira, analistas da William Blair escreveram que os resultados dos ensaios cl\u00ednicos dos medicamentos lan\u00e7am d\u00favidas sobre o seu futuro, apesar do otimismo da Sarepta. Eles acrescentaram: &quot;Consideramos a incapacidade do ensaio ESSENCE de atingir seu objetivo principal um desenvolvimento negativo.&quot;\u2019<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Embora a administra\u00e7\u00e3o esteja certa de que o Vyondys 53 e o Amondys 45 n\u00e3o perder\u00e3o sua autoriza\u00e7\u00e3o de comercializa\u00e7\u00e3o como resultado disso, permanecemos c\u00e9ticos e acreditamos que a rea\u00e7\u00e3o das a\u00e7\u00f5es (queda de 37% ap\u00f3s o fechamento do mercado) indica que os investidores tamb\u00e9m est\u00e3o preocupados com o futuro desses dois medicamentos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siga esta p\u00e1gina<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/pt\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Todos os ensaios cl\u00ednicos para distrofia muscular de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics&#8217; difficulties only get worse. In patients with Duchenne muscular dystrophy, the business found that their exon-skipping treatments, Vyondys 53 and Amondys 45, did not considerably enhance motor function. >>> Sarepta Announcement Tuesday&#8217;s pre-market trading saw the biotech selling at $15.60, a 36% decrease from Monday&#8217;s closing share price of $24.45. William Blair analysts [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5117,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[453,77,178,65,394],"class_list":["post-5115","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-amondys-45","tag-exon-skipping","tag-exon-skipping-therapies","tag-sarepta","tag-vyondys-53"],"subtitle":"Segundo a Sarepta, os pacientes com distrofia muscular de Duchenne n\u00e3o apresentaram uma melhora substancial na fun\u00e7\u00e3o motora com as terapias de exclus\u00e3o de \u00e9xons, Vyondys 53 e Amondys 45.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/5115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=5115"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/5115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/5117"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=5115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=5115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=5115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}